Graves’ disease is the most common cause of hyperthyroidism in children. Antithyroid drug (ATD) treatment is recommended as the initial treatment, leading to a marked improvement in most symptoms within 1 month of treatment initiation. Remission is achieved in 30% of children after a first course of ATD. Alternative treatments, such as radioactive iodine or thyroidectomy, are considered in cases of relapse, lack of compliance or ATD toxicity. The risk of relapse after a first course of ATD treatment for a median period of 2 years has been shown to be higher in patients with severe biochemical hyperthyroidism at diagnosis, young children and patients of non-Caucasian origin. Relapse risk decreases with the duration of the first course of ATD treatment, highlighting the positive impact of a long period of primary ATD treatment on outcome. The identification of predictive factors has made it possible to stratify patients according to the risk of relapse after ATD treatment, leading to improvements in patient management by facilitating the identification of patients requiring long-term ATD or early alternative therapy. Long-term careful follow-up is needed to determine the efficacy of disease management during childhood.

Keywords:
Graves’ disease, Antithyroid drug therapy, Recurrent hyperthyroidism
1.
Weetman AP: Graves’ disease. N Engl J Med 2000;343:1236–1248.
2.
Collen RJ, Landaw EM, Kaplan SA, Lippe BM: Remission rates of children and adolescents with thyrotoxicosis treated with antithyroid drugs. Pediatrics 1980;65:550–556.
3.
Hamburger JI: Management of hyperthyroidism in children and adolescents. J Clin Endocrinol Metab 1985;60:1019–1024.
4.
Zimmerman D, Gan-Gaisano M: Hyperthyroidism in children and adolescents. Pediatr Clin North Am 1990;37:1273–1295.
5.
Boiko J, Leger J, Raux-Demay MC, Cabrol S, Le Bouc Y, Czernichow P: Maladie de Basedow chez l’enfant: aspects cliniques et évolutifs. Arch Pediatr 1998;5:722–730.
6.
Lazar L, Kalter-Leibovici O, Pertzelan A, Weintrob N, Josefsberg Z, Phillip M: Thyrotoxicosis in prepubertal children compared with pubertal and postpubertal patients. J Clin Endocrinol Metab 2000;85:3678–3682.
7.
Rivkees SA, Dinauer C: An optimal treatment for pediatric Graves’ disease is radioiodine. J Clin Endocrinol Metab 2007;92:797–800.
8.
Lee JA, Grumbach MM, Clark OH: The optimal treatment for pediatric Graves’ disease is surgery. J Clin Endocrinol Metab 2007;92:801–803.
9.
Glaser NS, Styne DM: Predictors of early remission of hyperthyroidism in children. J Clin Endocrinol Metab 1997;82:1719–1726.
10.
Glaser NS, Styne DM: Predicting the likelihood of remission in children with Graves’ disease: a prospective, multicenter study. Pediatrics 2008;121:e481–e488.
11.
Kaguelidou F, Alberti C, Castanet M, Guitteny MA, Czernichow P, Leger J: Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. J Clin Endocrinol Metab 2008;93:3817–3826.
12.
Brix TH, Kyvik KO, Hegedus L: What is the evidence of genetic factors in the etiology of Graves’ disease? A brief review. Thyroid 1998;8:727–734.
13.
Brix TH, Kyvik KO, Christensen K, Hegedus L: Evidence for a major role of heredity in Graves’ disease: a population-based study of two Danish twin cohorts. J Clin Endocrinol Metab 2001;86:930–934.
14.
Saitoh O, Nagayama Y: Regulation of Graves’ hyperthyroidism with naturally occurring CD4+CD25+ regulatory T cells in a mouse model. Endocrinology 2006;147:2417–2422.
15.
Cooper DS: Hyperthyroidism. Lancet 2003;362:459–468.
16.
Lavard L, Ranlov I, Perrild H, Andersen O, Jacobsen BB: Incidence of juvenile thyrotoxicosis in Denmark, 1982–1988. A nationwide study. Eur J Endocrinol 1994;130:565–568.
17.
Wong GW, Cheng PS: Increasing incidence of childhood Graves’ disease in Hong Kong: a follow-up study. Clin Endocrinol (Oxf) 2001;54:547–550.
18.
Yang F, Shan Z, Teng X, Li Y, Guan H, Chong W, Teng D, Yu X, Fan C, Dai H, Yu Y, Yang R, Li J, Chen Y, Zhao D, Mao J, Teng W: Chronic iodine excess does not increase the incidence of hyperthyroidism: a prospective community-based epidemiological survey in China. Eur J Endocrinol 2007;156:403–408.
19.
Birrell G, Cheetham T: Juvenile thyrotoxicosis; can we do better? Arch Dis Child 2004;89:745–750.
20.
Lucidarme N, Ruiz JC, Czernichow P, Leger J: Reduced bone mineral density at diagnosis and bone mineral recovery during treatment in children with Graves’ disease. J Pediatr 2000;137:56–62.
21.
Cooper DS: Antithyroid drugs in the management of patients with Graves’ disease: an evidence-based approach to therapeutic controversies. J Clin Endocrinol Metab 2003;88:3474–3481.
22.
Cooper DS: Antithyroid drugs. N Engl J Med 2005;352:905–917.
23.
Brent GA: Clinical practice. Graves’ disease. N Engl J Med 2008;358:2594–2605.
25.
Sato H, Hattori M, Fujieda M, Sugihara S, Inomata H, Hoshi M, Miyamoto S: High prevalence of antineutrophil cytoplasmic antibody positivity in childhood onset Graves’ disease treated with propylthiouracil. J Clin Endocrinol Metab 2000;85:4270–4273.
26.
Nakamura H, Noh JY, Itoh K, Fukata S, Miyauchi A, Hamada N: Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves’ disease. J Clin Endocrinol Metab 2007;92:2157–2162.
27.
Laurberg P: Remission of Graves’ disease during anti-thyroid drug therapy. Time to reconsider the mechanism? Eur J Endocrinol 2006;155:783–786.
28.
Costello I, Wong IC, Nunn AJ: A literature review to identify interventions to improve the use of medicines in children. Child Care Health Dev 2004;30:647–665.
29.
Wang SH, Baker JR Jr: Targeting B cells in Graves’ disease. Endocrinology 2006;147:4559–4560.
30.
El Fassi D, Nielsen CH, Hasselbalch HC, Hegedus L: The rationale for B lymphocyte depletion in Graves’ disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. Eur J Endocrinol 2006;154:623–632.
31.
El Fassi D, Nielsen CH, Bonnema SJ, Hasselbalch HC, Hegedus L: B lymphocyte depletion with the monoclonal antibody rituximab in Graves’ disease: a controlled pilot study. J Clin Endocrinol Metab 2007;92:1769–1772.
32.
Rivkees SA: The management of hyperthyroidism in children with emphasis on the use of radioactive iodine. Pediatr Endocrinol Rev 2003;1(suppl 2):212–221; discussion 221–212.
33.
Read CH Jr, Tansey MJ, Menda Y: A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves’ patients. J Clin Endocrinol Metab 2004;89:4229–4233.
34.
Metso S, Jaatinen P, Huhtala H, Auvinen A, Oksala H, Salmi J: Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism. J Clin Endocrinol Metab 2007;92:2190–2196.
35.
Erbil Y, Ozluk Y, Giris M, Salmaslioglu A, Issever H, Barbaros U, Kapran Y, Ozarmagan S, Tezelman S: Effect of Lugol solution on thyroid gland blood flow and microvessel density in the patients with Graves’ disease. J Clin Endocrinol Metab 2007;92:2182–2189.
36.
Weetman AP: Graves’ hyperthyroidism: how long should antithyroid drug therapy be continued to achieve remission? Nat Clin Pract Endocrinol Metab 2006;2:2–3.
37.
Lippe BM, Landaw EM, Kaplan SA: Hyperthyroidism in children treated with long term medical therapy: twenty-five percent remission every 2 years. J Clin Endocrinol Metab 1987;64:1241–1245.
38.
Shulman DI, Muhar I, Jorgensen EV, Diamond FB, Bercu BB, Root AW: Autoimmune hyperthyroidism in prepubertal children and adolescents: comparison of clinical and biochemical features at diagnosis and responses to medical therapy. Thyroid 1997;7:755–760.
39.
Mussa GC, Corrias A, Silvestro L, Battan E, Mostert M, Mussa F, Pellegrino D: Factors at onset predictive of lasting remission in pediatric patients with Graves’ disease followed for at least three years. J Pediatr Endocrinol Metab 1999;12:537–541.
40.
Allahabadia A, Daykin J, Holder RL, Sheppard MC, Gough SC, Franklyn JA: Age and gender predict the outcome of treatment for Graves’ hyperthyroidism. J Clin Endocrinol Metab 2000;85:1038–1042.
41.
Nedrebo BG, Holm PI, Uhlving S, Sorheim JI, Skeie S, Eide GE, Husebye ES, Lien EA, Aanderud S: Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves’ disease. Eur J Endocrinol 2002;147:583–589.
42.
Kim TY, Park YJ, Park DJ, Chung HK, Kim WB, Kohn LD, Cho BY: Epitope heterogeneity of thyroid-stimulating antibodies predicts long-term outcome in Graves’ patients treated with antithyroid drugs. J Clin Endocrinol Metab 2003;88:117–124.
43.
Rotondi M, Chiovato L, Romagnani S, Serio M, Romagnani P: Role of chemokines in endocrine autoimmune diseases. Endocr Rev 2007;28:492–520.
44.
Luton D, Le Gac I, Vuillard E, Castanet M, Guibourdenche J, Noel M, Toubert ME, Leger J, Boissinot C, Schlageter MH, Garel C, Tebeka B, Oury JF, Czernichow P, Polak M: Management of Graves’ disease during pregnancy: the key role of fetal thyroid gland monitoring. J Clin Endocrinol Metab 2005;90:6093–6098.
45.
Abraham-Nordling M, Wallin G, Lundell G, Torring O: Thyroid hormone state and quality of life at long-term follow-up after randomized treatment of Graves’ disease. Eur J Endocrinol 2007;156:173–179.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.